3SBio Inc

F:83B Germany Biotechnology
Market Cap
$6.01 Billion
€5.85 Billion EUR
Market Cap Rank
#3015 Global
#268 in Germany
Share Price
€2.48
Change (1 day)
+4.20%
52-Week Range
€1.14 - €3.88
All Time High
€3.88
About

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER… Read more

3SBio Inc (83B) - Net Assets

Latest net assets as of June 2025: €18.94 Billion EUR

Based on the latest financial reports, 3SBio Inc (83B) has net assets worth €18.94 Billion EUR as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€23.83 Billion) and total liabilities (€4.89 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €18.94 Billion
% of Total Assets 79.49%
Annual Growth Rate 13.04%
5-Year Change 37.75%
10-Year Change N/A
Growth Volatility 6.28

3SBio Inc - Net Assets Trend (2016–2024)

This chart illustrates how 3SBio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for 3SBio Inc (2016–2024)

The table below shows the annual net assets of 3SBio Inc from 2016 to 2024.

Year Net Assets Change
2024-12-31 €18.04 Billion +9.22%
2023-12-31 €16.51 Billion +7.23%
2022-12-31 €15.40 Billion +5.07%
2021-12-31 €14.66 Billion +11.95%
2020-12-31 €13.09 Billion +26.39%
2019-12-31 €10.36 Billion +16.30%
2018-12-31 €8.91 Billion +16.75%
2017-12-31 €7.63 Billion +12.76%
2016-12-31 €6.77 Billion --

Equity Component Analysis

This analysis shows how different components contribute to 3SBio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 493.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings €10.78 Billion 69.83%
Other Components €4.66 Billion 30.17%
Total Equity €15.44 Billion 100.00%

3SBio Inc Competitors by Market Cap

The table below lists competitors of 3SBio Inc ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in 3SBio Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 14,033,771,000 to 15,436,258,000, a change of 1,402,487,000 (10.0%).
  • Net income of 2,090,320,000 contributed positively to equity growth.
  • Dividend payments of 555,088,000 reduced retained earnings.
  • Share repurchases of 242,448,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income €2.09 Billion +13.54%
Dividends Paid €555.09 Million -3.6%
Share Repurchases €242.45 Million -1.57%
Other Changes €109.70 Million +0.71%
Total Change €- 9.99%

Book Value vs Market Value Analysis

This analysis compares 3SBio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.38x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 0.85x to 0.38x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €2.91 €2.48 x
2018-12-31 €3.39 €2.48 x
2019-12-31 €3.79 €2.48 x
2020-12-31 €4.20 €2.48 x
2021-12-31 €4.85 €2.48 x
2022-12-31 €5.32 €2.48 x
2023-12-31 €5.85 €2.48 x
2024-12-31 €6.55 €2.48 x

Capital Efficiency Dashboard

This dashboard shows how efficiently 3SBio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 13.54%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 22.95%
  • • Asset Turnover: 0.38x
  • • Equity Multiplier: 1.57x
  • Recent ROE (13.54%) is above the historical average (12.13%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 10.92% 25.47% 0.25x 1.69x €60.31 Million
2017 12.65% 25.05% 0.27x 1.86x €195.71 Million
2018 14.83% 27.86% 0.33x 1.61x €415.72 Million
2019 10.12% 18.31% 0.36x 1.54x €11.21 Million
2020 7.82% 14.96% 0.32x 1.65x €-233.14 Million
2021 13.50% 25.87% 0.33x 1.57x €428.50 Million
2022 14.77% 27.92% 0.31x 1.70x €618.62 Million
2023 11.04% 19.82% 0.33x 1.68x €145.86 Million
2024 13.54% 22.95% 0.38x 1.57x €546.69 Million

Industry Comparison

This section compares 3SBio Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,291,084,078
  • Average return on equity (ROE) among peers: -24.49%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
3SBio Inc (83B) €18.94 Billion 10.92% 0.26x $4.45 Billion
09R (09R) $-3.01 Million 0.00% 0.00x $11.12 Million
IDORSIA AG (19T) $-968.72 Million 0.00% 0.00x $532.51 Million
1S90 (1S90) $-44.86 Million 0.00% 0.00x $51.72 Million
Strategic Partners A/S (1TB0) $14.24 Million -182.90% 0.36x $1.31 Million
25K0 (25K0) $-16.66 Million 0.00% 0.00x $102.39 Million
2BO (2BO) $-37.78 Million 0.00% 0.00x $6.23 Million
Intervacc AB (publ) (2E9) $237.93 Million -43.23% 0.09x $3.46 Million
2F5 (2F5) $-4.57 Million 0.00% 0.00x $2.14 Million
2H0 (2H0) $14.92 Million -17.30% 0.56x $9.25 Million
GNI Group Ltd (3G6) $13.72 Billion -1.46% 0.26x $772.60 Million